/
Oncology
Colorectal Cancer
357
Pipeline Programs↗
750
Active Trials↗
248
Companies Involved↗
Colorectal Cancer is a highly competitive landscape with 357 programs across 248 companies. The most active players are Merck & Co., Sichuan Baili Pharmaceutical Co., Ltd., Amal Therapeutics. 80 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Merck & Co.
4 programs
Sichuan Baili Pharmaceutical Co., Ltd.
3 programs
Amal Therapeutics
2 programs
Revolution Medicines
2 programs
Chipscreen Biosciences, Ltd.
1 program
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
1 program
Pipeline
Programs by Phase
Preclinical95
Phase 143
Phase 2139
Phase 380
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
241 of 310 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 310 classified programs, each share of the total. Modality classified for 94% of 357 pipeline programs.
Analysis
Trial Status
2,426
clinical trials
Completed962 · 40%
Recruiting404 · 17%
Unknown status367 · 15%
Terminated250 · 10%
Not yet recruiting185 · 8%
Active, not recruiting146 · 6%
Other112 · 5%
Clinical Trials
Trial Activity
2426 trials
Page 1 of 162
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)